{
    "cancer_info": {
        "cancer_name": "T-Cell Lymphomas"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Excisional or incisional biopsy",
            "Core needle biopsy (with ancillary techniques)",
            "Fine-needle aspiration (FNA) of periprosthetic effusion (BIA-ALCL)",
            "Immunohistochemistry (IHC) panels: CD20, CD3, CD10, BCL6, Ki-67, CD5, CD30, CD2, CD4, CD8, CD7, CD56, CD21, CD23, TCRβ/δ, PD-1, ALK, TP63, TFH markers (CD10, BCL6, PD-1, CXCL13, ICOS)",
            "Flow cytometry: CD45, CD3, CD5, CD19, CD10, CD20, CD30, CD4, CD8, CD7, subtype-specific markers (e.g., CD56 for ENKL, CD25 for ATLL)",
            "Molecular analysis: TCR gene rearrangement, ALK translocation (t(2;5)), DUSP22/TP63 rearrangements, EBER-ISH for EBV, HTLV-1 serology",
            "Next-generation sequencing (NGS): STAT3/STAT5B, PIK3CD, SETD2, INO80, TET3 mutations",
            "Viral testing: HTLV-1/2 serology, EBV DNA quantitative PCR",
            "Imaging: FDG PET/CT (preferred), diagnostic CT chest/abdomen/pelvis with contrast, MRI (head/neck for ENKL), ultrasound (breast for BIA-ALCL)",
            "Bone marrow biopsy and aspirate",
            "Laboratory tests: CBC with differential, LDH, comprehensive metabolic panel, uric acid, soluble IL-2R, EBV DNA load, pregnancy test",
            "Cardiac: MUGA scan or echocardiogram (if anthracycline planned)",
            "CNS evaluation: Lumbar puncture (if CNS involvement suspected)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "ALK+ ALCL (Stage I-II)",
            "risk_group": "All",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "CD30 positive",
                    "plan_name": "Brentuximab vedotin + CHP",
                    "plan_details": "Brentuximab vedotin 1.8 mg/kg (capped at 180 mg) on day 1, cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², prednisone 100 mg/m² for 5 days; every 21 days for 6 cycles ± involved-site RT (ISRT)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Multiagent chemotherapy ± RT",
                    "plan_details": "CHOP, CHOEP, or dose-adjusted EPOCH for 6 cycles ± ISRT (45-50 Gy)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other options"
                }
            ]
        },
        {
            "staging_criteria": "CD30+ PTCL (PTCL-NOS/AITL)",
            "risk_group": "All",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "CD30 positive",
                    "plan_name": "Brentuximab vedotin + CHP",
                    "plan_details": "Same regimen as for ALCL, 6 cycles",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "ATLL (Acute/Lymphoma subtype)",
            "risk_group": "High-risk by ATL-PI",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "CD30 positive",
                    "plan_name": "Brentuximab vedotin + CHP",
                    "plan_details": "6 cycles with CNS prophylaxis",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Dose-adjusted EPOCH",
                    "plan_details": "Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Responders",
                    "plan_name": "Allogeneic HCT",
                    "plan_details": "For eligible patients in CR/PR",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "ENKL (Stage I-II)",
            "risk_group": "Low-risk by PINK-E",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Nasal type",
                    "plan_name": "Asparaginase-based chemo + RT",
                    "plan_details": "SMILE, modified SMILE, P-GEMOX, or DDGP for 2-3 cycles → ISRT (45-50.4 Gy) → 2-4 additional chemo cycles",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "HSTCL",
            "risk_group": "All",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "ICE regimen",
                    "plan_details": "Ifosfamide, carboplatin, etoposide",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Responders",
                    "plan_name": "Allogeneic HCT",
                    "plan_details": "Strongly recommended",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory PTCL",
            "risk_group": "Transplant candidates",
            "treatment_plans": [
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "ALK+ ALCL",
                    "plan_name": "ALK inhibitors",
                    "plan_details": "Crizotinib, alectinib, or brigatinib",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "CD30+ disease",
                    "plan_name": "Brentuximab vedotin",
                    "plan_details": "Single agent (ORR 86% in ALCL)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "JAK/STAT+ PTCL",
                    "plan_name": "Ruxolitinib",
                    "plan_details": "JAK inhibitor (CBR 53-54%)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "CD30: Target for brentuximab vedotin; any positivity acceptable for treatment. ALK: Defines ALK+ ALCL (favorable prognosis); predicts response to ALK inhibitors. DUSP22 rearrangement: Favorable prognosis in ALK- ALCL. TFH markers (CD10, PD-1, CXCL13): Diagnose AITL/nodal TFH lymphomas; predict HDAC inhibitor sensitivity. STAT3/STAT5B mutations: Predict response to JAK inhibitors in T-LGLL/PTCL. EBV DNA load: Prognostic in ENKL (PINK-E index); high levels predict poor outcomes. HTLV-1+: Diagnostic for ATLL. CCR4+: Predicts response to mogamulizumab in ATLL. sIL-2R (CD25): Prognostic in ATLL (ATL-PI index). TCL1 overexpression: Diagnostic for T-PLL."
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：T细胞淋巴瘤.txt"
}